Kalaris Therapeutics, Inc. financial data

Symbol
KLRS on Nasdaq
Location
628 Middlefield Road, Palo Alto, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 780 % -18%
Debt-to-equity 96.9 % -62.5%
Return On Equity -201 % +77.2%
Return On Assets -87.8 % -38.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.7M shares -83.8%
Common Stock, Shares, Outstanding 18.7M shares -83.8%
Entity Public Float 58.8M USD -77.8%
Common Stock, Value, Issued 2K USD -81.8%
Weighted Average Number of Shares Outstanding, Basic 18.7M shares +1311%
Weighted Average Number of Shares Outstanding, Diluted 18.7M shares +1311%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.6M USD -70.2%
General and Administrative Expense 49.5M USD +99.1%
Operating Income (Loss) -81.3M USD +30%
Nonoperating Income (Expense) 906K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.3M USD -5.23%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -71.3M USD +37%
Earnings Per Share, Basic -8 USD/shares +83.3%
Earnings Per Share, Diluted -8 USD/shares +83.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 88.4M USD +1317%
Cash, Cash Equivalents, and Short-term Investments 118M USD -35.7%
Assets, Current 91.7M USD -29.5%
Property, Plant and Equipment, Net 673K USD -28.6%
Operating Lease, Right-of-Use Asset 495K USD -98.2%
Other Assets, Noncurrent 691K USD
Assets 92.8M USD -29.1%
Accounts Payable, Current 3.68M USD +3245%
Accrued Liabilities, Current 4.99M USD -50.5%
Liabilities, Current 7.65M USD +224%
Operating Lease, Liability, Noncurrent 8.34M USD -63.8%
Liabilities 39.7M USD +271%
Accumulated Other Comprehensive Income (Loss), Net of Tax -135K USD -118%
Retained Earnings (Accumulated Deficit) -138M USD +80.1%
Stockholders' Equity Attributable to Parent 53.1M USD
Liabilities and Equity 92.8M USD -29.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.44M USD -64.6%
Net Cash Provided by (Used in) Financing Activities 107M USD +1530%
Net Cash Provided by (Used in) Investing Activities 40M USD -4.13%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 18.7M shares -83.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 99.8M USD +4751%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 88.9M USD +1325%
Deferred Tax Assets, Valuation Allowance 157M USD -13.5%
Deferred Tax Assets, Gross 158M USD -12.7%
Operating Lease, Liability 9M USD -71.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.8M USD +69%
Lessee, Operating Lease, Liability, to be Paid 11M USD -69.7%
Property, Plant and Equipment, Gross 1.92M USD -0.83%
Operating Lease, Liability, Current 667K USD -92.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.3M USD +2.14%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.22M USD -72.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure -16.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.1M USD -34.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.38M USD +2.06%
Deferred Tax Assets, Operating Loss Carryforwards 100M USD +85.8%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -265K USD -126%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.46M USD +2.04%
Operating Lease, Payments 17M USD +254%
Additional Paid in Capital 191M USD -76.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 86K USD -81.5%
Deferred Tax Assets, Net of Valuation Allowance 1.86M USD +273%
Share-based Payment Arrangement, Expense 27M USD +29.5%
Interest Expense 1.44M USD +1750%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%